The investment will help accelerate the company’s suite of targeted alpha radiopharmaceuticals intended to treat numerous solid tumour types. Credit: peterschreiber.media via Shutterstock.

Aktis Oncology, a clinical-stage biotechnology company, has announced the successful closure of a $175m Series B financing round for advancing its radiopharmaceutical pipeline.

This oversubscribed and upsized funding aims to advance the company’s pipeline of targeted alpha radiopharmaceuticals designed to treat a wide variety of solid tumours.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The round was led by RA Capital Management, with RTW Investments and Janus Henderson Investors as co-leaders.

The investment will support the development of Aktis Oncology’s new radiopharmaceuticals, including a first-in-class Nectin-4-targeted miniprotein radioconjugate.

Aktis Oncology president and CEO Dr Matthew Roden said: “The overwhelming support from high-calibre investors underscores the progress we have made on our pipeline, platform, and supply chain capabilities, exemplified by the significant opportunity for AKY-1189, our first-in-class miniprotein alpha radioconjugate targeting Nectin-4 in development for several tumour types.

See Also:

“With over $300m in cash, we are well-positioned to prosecute several opportunities to expand the benefit of this exciting modality into new patient populations.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The financing attracted a select group of new investors, such as funds and accounts advised by Avidity Partners, T. Rowe Price Associates, and an undisclosed life sciences-focused investment fund.

All existing institutional investors participated, alongside strategic investors Eli Lilly and Company, Bristol Myers Squibb, and MRL Ventures Fund, the therapeutics-focused corporate venture fund of Merck.

With the new funding, RA Capital Management partner and managing director Andrew Levin will join the Aktis Oncology board of directors.

Additionally, Lauren Lee from RTW Investment and Vish Sridharan from Janus Henderson Investors will join as observers on the board.

In May this year, Eli Lilly signed a multi-target discovery collaboration agreement with Aktis Oncology to develop targets for radiopharmaceuticals discovered by the latter.